{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:57:34Z","timestamp":1789642654372,"version":"4.0.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jns.2015.05.034","type":"journal-article","created":{"date-parts":[[2015,5,31]],"date-time":"2015-05-31T11:36:25Z","timestamp":1433072185000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review"],"prefix":"10.1016","volume":"355","author":[{"given":"Wild\u00e9a Lice de Carvalho Jennings","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna Maria Vissoci","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Kallaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damacio Ram\u00f3n","family":"Kaimen-Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2015.05.034_bb0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2007.04.009","article-title":"Neuromyelitis optica: changing concepts","volume":"187","author":"Jacob","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/WCO.0b013e32814f1c6b","article-title":"Neuromyelitis optica","volume":"20","author":"Matiello","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3988\/jcn.2011.7.3.115","article-title":"New insights into neuromyelitis optica","volume":"7","author":"Kim","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2015.05.034_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2011.01.002","article-title":"Neuromyelitis optica: An update","volume":"303","author":"Mat\u00e0","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.autrev.2006.02.008","article-title":"Neuromyelitis optica \u2013 Devic's syndrome, update","volume":"5","author":"Mandler","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2015.05.034_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic's disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2009.08.045","article-title":"Neuromyelitis optica: effect of gender","volume":"286","author":"Wingerchuk","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0050","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of Neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","article-title":"The prevalence of neuromyelitis optica in South East Wales","volume":"19","author":"Cossburn","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1590\/S0004-282X2008000100034","article-title":"Devic's neuromyelitis optica: a critical review","volume":"66","author":"Lana-Peixoto","year":"2008","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2015.05.034_bb0065","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","article-title":"The prevalence of neuromyelitis optica in South East Wales","volume":"19","author":"Cossburn","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0085","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","article-title":"Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients","volume":"17","author":"Sahraian","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jnnp.73.4.429","article-title":"Optic neuromyelitis syndrome in Brazilian patients","volume":"73","author":"Papais-Alvarenga","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2015.05.034_bb0095","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1212\/WNL.0b013e3181fc2823","article-title":"Neuromyelitis optica and NMO-IgG in European pediatric patients","volume":"75","author":"Huppke","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.jns.2015.05.034_bb0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1590\/S0004-282X2012001000010","article-title":"The expanded spectrum of neuromyelitis optica \u2014 evidences for a new definition","volume":"70","author":"Lana-Peixoto","year":"2012","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2015.05.034_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ncn3.79","article-title":"Clinical spectrum of neuromyelitis optica 2013","volume":"2","author":"Weinshenker","year":"2014","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.jns.2015.05.034_bb0120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jns.2015.05.034_bb0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-010-1502-7","article-title":"Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature","volume":"29","author":"Sergio","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jns.2015.05.034_bb0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.02.018","article-title":"Neuromyelitis optica and astrocytic damage in its pathogenesis","volume":"306","author":"Fujihara","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0135","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2015.05.034_bb0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3143\/geriatrics.49.491","article-title":"A case of neuromyelitis optica associated with anti-aquaporin 4 antibody and other autoantibodies","volume":"49","author":"Maruta","year":"2012","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"10.1016\/j.jns.2015.05.034_bb0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0150","article-title":"Neuromyelitis optica spectrum disorders associated with other autoimmune diseases","author":"Freitas","year":"2014","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jns.2015.05.034_bb0155","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"Sato","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jns.2015.05.034_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","article-title":"The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes","volume":"34","author":"Sellner","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jns.2015.05.034_bb0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2010.11.004","article-title":"HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese","volume":"233","author":"Wang","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.jns.2015.05.034_bb0175","first-page":"146","article-title":"HLA-DRB1 typing in Caucasians patients with neuromyelitis optica","volume":"53","author":"Blanco","year":"2011","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1352458510382810","article-title":"Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population","volume":"17","author":"Deschamps","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1352458509350741","article-title":"HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis","volume":"16","author":"Brum","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0190","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1352458508102085","article-title":"Is neuromyelitis optica associated with human leukocyte antigen?","volume":"15","author":"Zephir","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","article-title":"Familial neuromyelitis optica","volume":"75","author":"Matiello","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/tan.12358","article-title":"No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population","volume":"84","author":"Namgoong","year":"2014","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jns.2015.05.034_bb0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0404.2006.00749.x","article-title":"Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies","volume":"115","author":"Szczucinski","year":"2007","journal-title":"Acta Neurol. Scand."},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2015.05.034_bb0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1086\/344266","article-title":"The chemokine system in neuroinflammation: an update","volume":"186","author":"Ransohoff","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jns.2015.05.034_bb0215","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1212\/WNL.57.8.1371","article-title":"Distinct chemokine receptor and cytokine expression profile in secondary progressive MS","volume":"57","author":"Sorensen","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0220","first-page":"3","article-title":"The chemokine system in experimental and clinical hematology","volume":"341","author":"Bruserud","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0002-9440(10)65249-2","article-title":"Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions","volume":"154","author":"Van Der Voorn","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2015.05.034_bb0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1044-5323(02)00125-2","article-title":"The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)","volume":"15","author":"Mahad","year":"2003","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0235","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.05.034_bb0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1399-0039.2004.00240.x","article-title":"Analysis of the monocyte chemoattractant protein 1\u20132518 promoter polymorphism in patients with multiple sclerosis","volume":"64","author":"Kroner","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jns.2015.05.034_bb0245","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jocn.2010.03.022","article-title":"Lack of association between monocyte protein-1 (MCP-1)-2518 A>G chemoattractant and C\u2013C chemokine receptor 2 (CCR2) Val64Ile polymorphisms and multiple sclerosis in a Tunisian population","volume":"17","author":"Messadi","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2015.05.034_bb0250","first-page":"1537","article-title":"Monocyte chemoattractant protein (MCP)-1-2518 A\/G SNP in Chinese Han patients with VKH syndrome","volume":"15","author":"Hou","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jns.2015.05.034_bb0255","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0198-8859(03)00090-9","article-title":"MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis","volume":"64","author":"Gonz\u00e1lez-Escribano","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0260","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.nbd.2009.10.013","article-title":"Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica","volume":"37","author":"Kim","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2015.05.034_bb0265","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2990.2012.01304.x","article-title":"Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases","volume":"39","author":"Park","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jns.2015.05.034_bb0270","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.4049\/jimmunol.136.8.3085","article-title":"Gene mapping and somatic cell hybrid analysis of the role of human lymphocyte function-associated antigen-3 (LFA-3) in CTL-target cell interactions","volume":"136","author":"Barbosa","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0275","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"Hafler","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.05.034_bb0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2377-14-57","article-title":"CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jns.2011.11.005","article-title":"Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese\u2014a case control study","volume":"314","author":"Wang","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0290","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaci.2005.12.1346","article-title":"IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity","volume":"117","author":"Kawaguchi","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10875-007-9125-8","article-title":"The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis","volume":"28","author":"Arisawa","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0300","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/ken512","article-title":"Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand","volume":"48","author":"Nordang","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jns.2015.05.034_bb0305","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s10156-006-0475-6","article-title":"Post-dengue neuromyelitis optica: case report of a Japanese-descendent Brazilian child","volume":"12","author":"De Sousa","year":"2006","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.jns.2015.05.034_bb0310","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jocn.2009.12.024","article-title":"Neuromyelitis optica associated with subacute human T-lymphotropic virus type 1 infection","volume":"17","author":"Olindo","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2015.05.034_bb0315","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2011.06.045","article-title":"Seropositive antiaquaporin-4 antibody associated with multisegmental myelitis in a patient with paracoccidioidomycosis","volume":"309","author":"Brum","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0320","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.5588\/ijtld.10.0780","article-title":"Neuromyelitis optica and pulmonary tuberculosis: a case\u2013control study","volume":"15","author":"Zatjirua","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.jns.2015.05.034_bb0325","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1352458513483891","article-title":"Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections","volume":"19","author":"Feyissa","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0330","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"Zhang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2015.05.034_bb0335","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.05.034_bb0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.05.034_bb0345","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0350","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0355","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optics attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jns.2015.05.034_bb0360","doi-asserted-by":"crossref","first-page":"e23489","DOI":"10.1371\/journal.pone.0023489","article-title":"The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis","volume":"6","author":"Storoni","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jns.2015.05.034_bb0365","doi-asserted-by":"crossref","first-page":"e74773","DOI":"10.1371\/journal.pone.0074773","article-title":"Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders","volume":"8","author":"Tzartos","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2015.05.034_bb0370","first-page":"99","article-title":"Detection of anti-aquaporin-4 antibodies in Neuromyelitis optica: current status of the assays","volume":"15","author":"Waters","year":"2008","journal-title":"Int. MS J."},{"key":"10.1016\/j.jns.2015.05.034_bb0375","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cca.2012.04.027","article-title":"Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica","volume":"415","author":"Gonz\u00e1lez","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jns.2015.05.034_bb0380","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jns.2015.05.034_bb0385","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2015.05.034_bb0390","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1590\/S0004-282X2008000300001","article-title":"Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica","volume":"66","author":"Adoni","year":"2008","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2015.05.034_bb0395","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis","volume":"70","author":"Matiello","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0400","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00415-010-5780-4","article-title":"Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients","volume":"258","author":"Akman-Demir","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0405","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1468-1331.2011.03479.x","article-title":"Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases","volume":"19","author":"Dellavance","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0415","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2015.05.034_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jns.2015.05.034_bb0430","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0440","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12118","article-title":"Immunology of neuromyelitis optica: a T cell-B cell collaboration","volume":"1283","author":"Mitsdoerffer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0445","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jns.2015.05.034_bb0450","doi-asserted-by":"crossref","first-page":"e16083","DOI":"10.1371\/journal.pone.0016083","article-title":"Functional characterization of aquaporin-4 specific T cells: towards a model for NEUROMYELITIS OPTICA","volume":"6","author":"Kalluri","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2015.05.034_bb0455","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00401-011-0824-0","article-title":"Pathogenic T cell responses against aquaporin 4","volume":"122","author":"Pohl","year":"2011","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2015.05.034_bb0460","first-page":"862169","article-title":"Where do AQP4 antibodies fit in the pathogenesis of NMO?","volume":"2012","author":"Kinoshita","year":"2012","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jns.2015.05.034_bb0465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","article-title":"Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis","volume":"234","author":"Li","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0470","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T, cell responses in the central nervous system","volume":"9","author":"Goverman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0475","doi-asserted-by":"crossref","first-page":"e15531","DOI":"10.1371\/journal.pone.0015531","article-title":"Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis","volume":"5","author":"Domingues","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2015.05.034_bb0480","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0485","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.3390\/ijms131012213","article-title":"Interferon-\u03b21b increases Th2 response in neuromyelitis optica","volume":"13","author":"Nakajima","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2015.05.034_bb0490","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000329576","article-title":"Association of Th1\/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica","volume":"66","author":"Shimizu","year":"2011","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0495","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.biocel.2012.06.013","article-title":"Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies","volume":"44","author":"Ratelade","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jns.2015.05.034_bb0500","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood\u2013brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0505","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/immu.1994.1004","article-title":"Heterogeneity of human IgG Fc receptors","volume":"4","author":"Capel","year":"1994","journal-title":"ImmunoMethods"},{"key":"10.1016\/j.jns.2015.05.034_bb0510","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2169\/internalmedicine.51.5636","article-title":"Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent pneumococcal polysaccharide vaccination","volume":"51","author":"Kitazawa","year":"2012","journal-title":"Intern. Med."},{"key":"10.1016\/j.jns.2015.05.034_bb0515","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2015.05.034_bb0520","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2015.05.034_bb0525","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0530","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2015.05.034_bb0535","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jns.2015.05.034_bb0540","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","article-title":"Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica","volume":"286","author":"Ratelade","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2015.05.034_bb0545","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Brazilian committee for treatment and research in multiple sclerosis. Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2011","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2015.05.034_bb0550","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0555","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2011.12.010","article-title":"Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network","volume":"243","author":"Muls","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0560","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jca.21215","article-title":"Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica","volume":"27","author":"Khatri","year":"2012","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jns.2015.05.034_bb0565","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","article-title":"The rescue effect of plasma exchange for neuromyelitis optica","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2015.05.034_bb0570","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0575","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.05.034_bb0580","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0585","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0590","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2377-14-51","article-title":"Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate","volume":"14","author":"Ramanathan","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0595","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7224\/1537-2073-2.4.43","article-title":"Treatment of Devic's disease with methotrexate and prednisone","volume":"2","author":"Minagar","year":"2000","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.jns.2015.05.034_bb0600","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Aegis of French national observatory of multiple sclerosis. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2015.05.034_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0610","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2015.05.034_bb0615","first-page":"1076","article-title":"The treatment of neuromyelitis optica: present and future perspective","volume":"2","author":"Akaishi","year":"2014","journal-title":"J. Neurol. Disord. Stroke"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2015.05.034_bb0620","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jns.2015.05.034_bb0625","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","article-title":"Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein","volume":"18","author":"Herges","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0630","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.mehy.2011.02.027","article-title":"Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica","volume":"76","author":"Wang","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jns.2015.05.034_bb0635","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0640","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2015.05.034_bb0645","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","article-title":"Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica","volume":"26","author":"Tradtrantip","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.jns.2015.05.034_bb0650","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(00)80541-5","article-title":"Humoral immunity due to long-lived plasma cells","volume":"8","author":"Slifka","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2015.05.034_bb0655","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1476-9255-6-18","article-title":"TNF-\u03b1 and IL-10 downregulation and marked oxidative stress in neuromyelitis optica","volume":"6","author":"Pent\u00f3n-Rol","year":"2009","journal-title":"J. Inflamm."},{"issue":"5","key":"10.1016\/j.jns.2015.05.034_bb0660","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.jns.2015.05.034_bb0665","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF02918257","article-title":"Membrane defence against complement lysis: the structure and biological properties of CD59","volume":"12","author":"Davies","year":"1993","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jns.2015.05.034_bb0670","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-11-16","article-title":"Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G","volume":"11","author":"Asavapanumas","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2015.05.034_bb0675","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1352458508096875","article-title":"Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation","volume":"15","author":"Fagius","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2015.05.034_bb0680","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","article-title":"Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus","volume":"70","author":"Illei","year":"2011","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15003299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15003299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:49:05Z","timestamp":1691714945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15003299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":136,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0022510X15003299"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.05.034","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}